Clinical Trial Research
Rheoscience and Dr. Reddy's Commence the First Phase III Trial of Balaglitazone (DRF 2593)
Published in Lab Business Week, August 19th, 2007
Rheoscience A/S and Dr. Reddy's Laboratories (NYSE:RDY) announced that the first patient has been dosed in a Phase III study with Balaglitazone (DRF2593-307), which is an insulin sensitizer that acts as a partial PPAR (peroxisome proliferator-activated receptor) gamma agonist. The study is the first in a series of planned Phase III trials which will investigate the safety and efficacy of Balaglitazone, as an oral anti-diabetic drug.
Balaglitazone is a second generation of PPAR gamma agonist with only partial agonistic properties, which in clinical phase II studies have shown to have glucose lowering capabilities and to be body-weight neutral. In preclinical experiments,...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Lab Business Week
Source: Lab Business Week (2007-08-19)
More Articles from Lab Business Week
- Allergies
Auriga Laboratories Expands the Zinx Family with the Launch of Two New Prescription Convenience Kits - Zinx Allergy Kit and Zinx Kids' Sneeze Kit - Antibiotics
Findings from Dr. Reddy's Laboratories Ltd. advance knowledge in antibiotics - Breast Cancer Therapy
Research conducted at Chester Beatty Laboratories has updated our knowledge about breast cancer therapy - Cell Biology
Cold Spring Harbor Laboratory reports research in cell biology - Chemotherapy
Reports outline chemotherapy research from Mitsubishi Kagaku Bio-Clinical Laboratories, Inc. - Drug Resistance
Study results from JMI Laboratories Inc. broaden understanding of drug resistance - More from this issue of Lab Business Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
